Floatz logo

Tas-102

Kidney Neoplasms

PfizerunclassifiedPhase 3Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Kidney Neoplasms cohort.

Asset / SponsorPhaseRating
Axitinib
Pfizer
Phase 3BB
Ipilimumab
Pfizer
Phase 4BB
Nivolumab
Bristol-Myers Squibb
Phase 4BB
su011248
Pfizer
Phase 3BB
FENTANYL
RenJi Hospital
Phase 4BB

View all 47 →

Same molecule, other indications

Tas-102 is also rated in:

Stage IV Renal Cell CancerDormant
BB
Indicative ·
68 / 100
View asset →
Stage IV Non-Small Cell Lung Cancer AJCC v7Dormant
BB
Indicative ·
68 / 100
View asset →
Carcinoma, Islet CellDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →